[
    [
        {
            "time": "",
            "original_text": "生医医药行业周报：第四批集采正式开标 拟中标药品平均降幅52%符合预期",
            "features": {
                "keywords": [
                    "生物医药",
                    "集采",
                    "降幅",
                    "中标"
                ],
                "sentiment_score": -0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "生医医药行业周报：第四批集采正式开标 拟中标药品平均降幅52%符合预期",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022-02-09",
            "original_text": "凯莱英(002821.SZ)17.6万股限制性股票将于2月9日上市",
            "features": {
                "keywords": [
                    "凯莱英",
                    "限制性股票",
                    "上市"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)17.6万股限制性股票将于2月9日上市",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：新冠变异后是否需要常态化免疫加强？智飞新高后继续强烈看好",
            "features": {
                "keywords": [
                    "医药生物",
                    "新冠变异",
                    "免疫加强",
                    "智飞"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：新冠变异后是否需要常态化免疫加强？智飞新高后继续强烈看好",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]